In-House Prostate Fusion: Capture the Best of Both Worlds—Accuracy and Cost-Effectiveness
MRI-US fusion is clinically proven to detect higher rates of high-grade prostate cancer compared to traditional ultrasound-guided biopsies. While in-house fusion is widely recognized for providing unmatched access and clinical benefits to patients, many practices simply can’t afford the costs and additional staffing that come with a new fusion system — that’s where Navigo comes in.
Navigo was specifically designed to remove barriers to in-office fusion by offering the ultimate in ease of use, scheduling efficiency, and affordability — delivering benefits for both patients and practices.
Schedule a call to find out how Navigo can:
Enhance your biopsy precision by compensating for patient movement in real time
Safeguard your bottom line with low upfront costs and new practice revenue streams
Streamline your fusion workflow by eliminating manual repositioning, re-registration and biopsy marking
Schedule a Navigo Discovery Call
CPT Code 55700 for prostate biopsy will be eliminated soon.
Is your practice prepared?
The AMA recently announced the addition of 9 new prostate biopsy CPT® codes. Urology practices that haven’t adopted fusion biopsy technology – such as Navigo’s real-time 4D fusion navigation system – are at risk of revenue loss due to the impact the changes will have on procedure reimbursements beginning Jan. 1, 2026. Interested in exploring an affordable, effective option for in-house fusion biopsy? Schedule a demo:
Prostate Fusion Navigation Systems: A Comparison Guide
Evaluate the best prostate fusion navigation system for your urology practice with this comparison of Navigo and other available systems.
Are you evaluating alternatives to UroNav, Koelis Trinity or another fusion biopsy navigation system?
Schedule a demo to see first-hand how Navigo stacks up.
.webp)
UROLOGY WHITE PAPER
Why Bringing Prostate MRI-US Fusion Procedures In-House Makes Clinical and Business Sense
Download this new white paper to learn how moving fusion biopsies in-house can:
Significantly increase prostate cancer detection rates
Simplify patient scheduling and increase practice efficiency
Build new revenue streams to optimize practice profitability
